GlassScriptPhysician profile
Rohanjit Sidhu
NPI 1417370958
$457.66
in general payments reported to CMS, 2019-2025
9 companies · $232 in 2025
The $232 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $65.86 · 2022: $104 · 2023: $55.77 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $287.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $96.17 | 2021-2022 | |
| Amgen INC. | $60.67 | 2025 | Krystexxa |
| Boston Scientific Corporation | $55.77 | 2023 | Watchman Flx |
| Pfizer INC. | $54.66 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $53.62 | 2025 | Jynarque, Rexulti |
| Glaxosmithkline, LLC. | $50.41 | 2025 | Benlysta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.55 | 2022-2025 | Jardiance |
| Neurocrine Biosciences, INC. | $28.38 | 2025 | |
| Travere Therapeutics, INC. | $15.43 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohanjit Sidhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.